FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Nicotine Dependence NDA Gets Complete Response Letter

[ Price : $8.95]

FDA sends Achieve Life Sciences a Complete Response Letter on its NDA for cytisinicline as a treatment for nicotine dependence.

Pharmaneek Inspection Form FDA-483 Out

[ Price : $8.95]

FDA releases the form FDA-483 with two observations from an inspection at the Pharmaneek non-sterile drug manufacturing facility i...

FDA Nixes Enforcement Action Against Whoop's Blood Pressure Feature

[ Price : $8.95]

FDA closes a potential enforcement action against Whoop Inc., reversing an earlier regulatory position that raised questions about...

Expand Real-World Evidence Use in Drug Approvals: Article

[ Price : $8.95]

Drug company executives recommend ways FDA could increase the use of real-world evidence in regulatory decisions.

Jubilant HollisterStier CGMP Issues

[ Price : $8.95]

FDA warns Canadas Jubilant HollisterStier General Partnership about CGMP violations in its manufacturing of finished drugs.

HHS Unveils Initiative to Accelerate U.S. Clinical Trials

[ Price : $8.95]

HHS unveils a broad, department-wide initiative aimed at speeding clinical research, reducing regulatory barriers, and attracting ...

Guide on Using Quantitative Systems Pharmacology Models for Trial Dosing

[ Price : $8.95]

FDA posts a draft guidance outlining how sponsors can use quantitative systems pharmacology models to determine starting doses for...

FDA Revises Guide on Demonstrating Drug Effectiveness

[ Price : $8.95]

FDA publishes a revised draft guidance that updates how sponsors can demonstrate "substantial evidence" of effectiveness for new d...

Agency Updates Draft Guidance on Master Protocols

[ Price : $8.95]

The agency releases a revised draft guidance aimed at helping sponsors design and conduct clinical trials using master protocols, ...